Blog post
Blenrep for Myeloma: Uses, Side Effects & Status
What Is Blenrep (belatanmab mafodotin) and How Does It Work?
Blenrep® (belantamab mafodotin) is a monoclonal antibody that targets B-cell maturation antigen (BCMA)…
Blog post
The State of Myeloma in 2024 Two new FDA approvals and promising clinical trials bode well for the future By Dr. Joseph Mikhael, IMF Chief Medical Officer The pace of change in the field of myeloma is incredible! New…
Blog post
As a result of the Inflation Reduction Act (IRA), which was signed into law in 2022, patients with Medicare Part D prescription drug plans can now “benefit from lower prescription drug costs and a…
Blog post
Myeloma Research Updates: Key Takeaways from ASCO, EHA & IMWG
Every year, three annual events that take place in quick succession hold a special significance for the researchers and clinicians working in the field of myeloma. The 2025 annual meeting of the American Society of…
Blog post
On Tuesday, July 1, the International Myeloma Foundation conducted its annual webinar on “Top Myeloma Research Presented at ASCO, EHA, & IMWG 2025 Webinar: The Patient…
Blog post
Key Myeloma Research Highlights from the 2024 ASH Annual Meeting
Every December, the international hematology community comes together to share the latest and greatest in research.
With an expected 35,000 attendees in San Diego this week, there is no doubt that this year’s 66th…
Blog post
July and August 2025: What’s New in Myeloma? At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage,…
Blog post
Key Takeaways from the 2025 IMWG, ASCO, and EHA ConferencesEvery year, three annual events take place in quick succession — ASCO, IMWG, and EHA. These highly-anticipated meetings hold special significance for researchers and clinicians working in the field of myeloma. …
Blog post
October and November 2025: What’s New in Myeloma? At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of…
Blog post
At the end of each month, the International Myeloma Foundation (IMF) brings you the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage, and resilience to the myeloma community. Through these…
Blog post
At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage, and resilience to the myeloma community.
…
Blog post
On Tuesday, June 17, the International Myeloma Foundation (IMF) conducted its annual webinar on the 2025 IMWG Conference Series: Making Sense of Treatment.
The webinar was hosted by IMF Chief Medical Officer Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO (TGen at the City of…
Blog post
At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage, and resilience to the myeloma…
Videos
The DREAMM-7 study (NCT04246047) compared the efficacy and safety of belantamab mafodotin (BVd) versus daratumumab (DVd) in relapsed/refractory multiple myeloma (MM) patients who had received at least one prior line of therapy. BVd demonstrated superior progression-free survival (PFS)…
News Article
Positive Results from the DREAMM-8 Phase III Trial of Blenrep in Myeloma Treatment
In a March 7, 2024 press release from GSK, the following was reported: "Positive headline results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating…
News Article
Health Canada Approves Blenrep (belantamab mafodotin) Combinations for Relapsed or Refractory Multiple Myeloma
July 23, 2025—According to a press release from GSK, "Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with…
News Article
July 24, 2025—According to a press release from GSK, Blenrep (belantamab mafodotin) has been approved "in the European Union (EU) for the treatment of adults with relapsed or refractory multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have received…
News Article
On February 5, 2024, GSK announced results from an interim analysis of the DREAMM-7 phase III head-to-head trial evaluating belantamab mafodotin combined with bortezomib plus dexamethasone (BorDex) versus daratumumab plus BorDex in second-line and later treatment of relapsed or refractory…
U.S. FDA Extends Review Period for Blenrep (belantamab mafodotin) for Relapsed or Refractory Myeloma
News Article
FDA Extends Review Period for Blenrep (belantamab mafodotin) for Relapsed or Refractory Myeloma
July 23, 2025—According to a press release from GSK, "the US Food and Drug Administration (FDA) has extended the review period for the Biologics License…
Videos
Abstract Title:
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)
Summary…
Videos
Abstract Title:
DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM)
…
News Article
Blenrep Shows Promise in DREAMM-7 Trial for Relapsed Myeloma Patients
On November 27, 2023, GSK announced positive results from the DREAMM-7 phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma. The…
News Article
On Thursday, October 23, 2025, the U.S. Food and Drug Administration (FDA) announced its approval…
Videos
Comparing the Safety and Efficacy of Belamaf to Pd in RRMM
Evaluating the phase 3, open-label, randomized DREAMM-3 study
Dr. Katja Weisel presented a study evaluating the efficacy and safety of single-agent belantamab mafodotin (belamaf) (a first-…
Videos
Belantamab & CAR T-Cell Therapy: Key ASH 2024 Updates on Early Myeloma Relapse
IMF Chief Medical Officer Dr. Joseph Mikhael breaks down major findings on early relapse from the 2024 American Society of Hematology (ASH).
IMF…
News Article
IMF Presents Top Ten Oral and Poster Abstracts at the 2024 ASH Annual Meeting
Oral and poster abstracts co-authored by IMF President & CEO and 29-year myeloma patient Yelak Biru, IMF Chief Medical Officer Dr. Joseph Mikhael, and members of the IMF…
News Article
Blenrep Withdrawal: What Myeloma Patients Need to Know
On November 22, 2022, GSK announced it has initiated the process for withdrawal of the U.S. marketing…
Videos
Early Relapsed Multiple Myeloma: What’s Changing in 2025 | Research Breakthroughs from ASCO & EHA
Are you or a loved one navigating a multiple myeloma relapse after one to three prior treatments?
In this video, Dr. Joseph Mikhael, Chief Medical…
Page
POMALYST® (also known as pomalidomide, its generic drug name) is an immunomodulatory agent taken by mouth in capsule form. It is used to treat adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 2 prior therapies, including the immunomodulatory agent…
Videos
Top 10 Myeloma Breakthroughs from ASCO & EHA: Frontline Therapy, Early & Late Relapse, and CAR T-cell Insights
Interested in the latest breakthroughs presented at ASCO and EHA this year? Dr. Joseph Mikhael, IMF Chief Medical Officer, condenses the top 10…
Videos
Watch the Replay: Discover the Latest Myeloma Research at ASH — Insights for Patients & Families
In case you missed it, IMF Chief Medical Officer Dr. Joseph Mikhael and our support group leaders went live on Facebook on the evening of Monday, December 9, to discuss the key myeloma…
Videos
The study DREAMM-9 evaluates belantamab mafodotin (belamaf) in combination with VRd for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplant (ASCT). It explores various dosing schedules and reports favorable safety profiles with notable ocular events.…
Videos
DREAMM-9 Study for Newly Diagnosed Multiple Myeloma
Evaluating Belantamab mafodotin with VRd or Rd
Dr. Saad Usmani presents the results of an ongoing Phase One randomized open-label study. The study aims to evaluate the safety and tolerability…